Squarepoint Ops LLC Has $360,000 Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)

Squarepoint Ops LLC lowered its stake in Verve Therapeutics, Inc. (NASDAQ:VERV) by 11.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 73,810 shares of the company’s stock after selling 9,990 shares during the period. Squarepoint Ops LLC owned 0.09% of Verve Therapeutics worth $360,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Verve Therapeutics by 8.1% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,592,198 shares of the company’s stock valued at $34,424,000 after buying an additional 194,594 shares during the period. PBCay One RSC Ltd bought a new stake in Verve Therapeutics during the 4th quarter worth about $96,000. ProShare Advisors LLC raised its holdings in Verve Therapeutics by 31.0% during the 1st quarter. ProShare Advisors LLC now owns 17,696 shares of the company’s stock worth $235,000 after purchasing an additional 4,184 shares during the last quarter. Vanguard Group Inc. lifted its position in Verve Therapeutics by 15.7% during the 1st quarter. Vanguard Group Inc. now owns 6,331,312 shares of the company’s stock valued at $84,080,000 after purchasing an additional 859,382 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Verve Therapeutics in the 1st quarter valued at about $191,000. Institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Stock Up 0.7 %

Shares of NASDAQ VERV opened at $4.60 on Friday. Verve Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $20.12. The stock has a market cap of $389.25 million, a price-to-earnings ratio of -1.60 and a beta of 1.80. The company’s fifty day moving average is $5.28 and its 200-day moving average is $6.20.

Verve Therapeutics (NASDAQ:VERV) last posted its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.09. The firm had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $2.40 million. Verve Therapeutics had a negative return on equity of 35.20% and a negative net margin of 933.08%. The company’s revenue was up 219.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.87) earnings per share. On average, research analysts anticipate that Verve Therapeutics, Inc. will post -2.65 EPS for the current fiscal year.

Analyst Ratings Changes

VERV has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Verve Therapeutics in a report on Monday, August 12th. Canaccord Genuity Group decreased their price objective on Verve Therapeutics from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, Royal Bank of Canada cut their target price on Verve Therapeutics from $25.00 to $20.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $26.00.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.